AG
KNSA icon

Artal Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Artal Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100,000
Closed -$1.74M – 115
2018
Q2 		$1.74M Buy
+100,000
New +$1.81M 0.04% 95

Other funds holding KNSA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group's KNSA Position: Q3 2018 in Review

Artal Group sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2018, closing a stake of 100,000 shares — an estimated $1.74M sold.

Artal Group first reported a position in KNSA in Q2 2018 and held it in 1 quarter. The position peaked at $1.74M in Q2 2018. 55 funds tracked by Wall St. Rank hold KNSA as of Q3 2018.

  • Artal Group reported no remaining Kiniksa Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Artal Group sold 100,000 Kiniksa Pharmaceuticals shares in Q3 2018, an estimated $1.74M.
  • Artal Group first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Artal Group's Kiniksa Pharmaceuticals position peaked at $1.74M in Q2 2018.
  • 55 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2018.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.